Abstract:Objective To observe brain-derived neurotrophic factor ( BDNF) on the behavior of rats with L-DOPA induced dyskinesia and investigating its mechanism. Methods Hemi-parkinsonian rat models were established by stereotaxically injection of 6-hydroxy dopamine(6-OHDA) in the right medial forebrain bundle. The Parkinson's disease model rats were randomly divided into four groups: L-DOPA group ,L-DOPA+BDNF group, BDNF group and normal saline group. L-DOPA group and L-DOPA + BDNF group were injected with L-DOPA 25 mg / kg +benserazide 6. 25 mg / kg, BDNF group and saline group were injected the same volume of saline. All rats received intraperitoneal injections twice daily and continued for 21 days. At 2,11,21,23 and 29 days, abnormal involuntary movement ( AIM ) score and stepped experiment were detected. The TrkB protein phosphorylation levels of rat striatum tissue were detected by western blot. Results There was no involuntary movement in normal saline group and BDNF group. There was no statistical significance of the differences of AIM scores between L-DOPA group and L-DOPA+BDNF group at 2 d,11 d,21 d. Compared with L-DOPA group, the body, axial and tongue AIM scores at 23 d and the axial, tongue AIM scores at 29 d were significantly decreased in rats of L-DOPA+BDNF group ( all P<0. 05). There was no change of left forelimb step number in normal saline group and BDNF group after injection. Compared with before injection, the left forelimb step numbers of L-DOPA group and L-DOPA+ BDNF group weresignificantly increased at each time point after injection ( all P<0. 05 ) . The left forelimb step numbers of 4 groups showed a downtrend in the treatment. Compared with L-DOPA group and normal saline group, the pTrkB protein levels in damaged striatum tissues were increased in L-DOPA+BDNF group and BDNF group (all P<0. 05). There was no significant difference of pTrkB protein levels in damaged striatum tissues between BDNF group and L-DOPA+BDNF group and also between L-DOPA group and normal saline group. There was no significant difference of pTrkB protein levels in sound striatum among the 4 groups . There was no significant difference of TrkB protein levels among the 4 groups. Conclusion Exogenous administration of BDNF can alleviate abnormal involtmtary movements induced by L-DOPA without disturbing the efficacy of L-DOPA, which may be associated with activation of BDNF-TrkB signaling pathways.

AAV–BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment

Targeted Retrograde Transfection of Adenovirus Vector Carrying Brain-Derived Neurotrophic Factor Gene Prevents Loss of Mouse (twy/twy) Anterior Horn Neurons in Vivo Sustaining Mechanical Compression.

Intracerebral Transplantation of BDNF-overexpressing Human Neural Stem Cells (HB1.F3.BDNF) Promotes Migration, Differentiation and Functional Recovery in a Rodent Model of Huntington's Disease.

Effect of Brain-Derived Neurotrophic Factor on Tyrosine Kinase B and Endogenous Brain-Derived Neurotrophic Factor Expressions by Lateral Ventricle Infusion into AD Mice

1H-MRS Assessment of the Therapeutic Effect of Bilateral Intraventricular BDNF Infusion into APP/PS1 Double Transgenic Mice

Pharmacological Co-Activation of TrkB and TrkC Receptor Signaling Ameliorates Striatal Neuropathology and Motor Deficits in Mouse Models of Huntington's Disease

Post-symptomatic Delivery of Brain-Derived Neurotrophic Factor (BDNF) Ameliorates Spinocerebellar Ataxia Type 1 (SCA1) Pathogenesis

Intrathecal delivery of AAV-NDNF ameliorates disease progression of ALS mice

Transfection of the BDNF Gene in the Surviving Dopamine Neurons in Conjunction with Continuous Administration of Pramipexole Restores Normal Motor Behavior in a Bilateral Rat Model of Parkinson's Disease

Retracted: 1h-Mrs Can Monitor Metabolites Changes Of Lateral Intraventricular Bdnf Infusion Into A Mouse Model Of Alzheimer'S Disease In Vivo(Retracted Article. See Vol. 254, Pg. 477, 2013)

Bone Marrow Mesenchymal Stem Cells Can Improve the Motor Function of a Huntington's Disease Rat Model

Effects of brain-derived neurotrophic factor on the behavior of rats with L-DOPA induced dyskinesia and its mechanism

Therapeutic Efficacy Of Aav8-Mediated Intrastriatal Delivery Of Human Cerebral Dopamine Neurotrophic Factor In 6-Ohda-Induced Parkinsonian Rat Models With Different Disease Progression

MPTP‐induced Deficits in Striatal Synaptic Plasticity Are Prevented by Glial Cell Line‐derived Neurotrophic Factor Expressed Via an Adeno‐associated Viral Vector

BDNF-Regulated Modulation of Striatal Circuits and Implications for Parkinson's Disease and Dystonia

Region-specific pro-survival signaling and global neuronal protection by wild-type Huntingtin

Recombinant AAV-mediated Expression of Human BDNF Protects Neurons Against Cell Apoptosis in Aβ-induced Neuronal Damage Model

Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor

AAV-Mediated Restoration of Dystrophin-Dp71 in the Brain of Dp71-Null Mice: Molecular, Cellular and Behavioral Outcomes

Do BDNF and NT-4/5 exert synergistic or occlusive effects on corticostriatal transmission in a male mouse model of Huntington's disease?

Delivery of CDNF by AAV-mediated gene transfer protects dopamine neurons and regulates ER stress and inflammation in an acute MPTP mouse model of Parkinson's disease